John K. Wiencke
YOU?
Author Swipe
View article: 1123 Methylation cytometry enhances prediction of immunotherapy response in head and neck cancer
1123 Methylation cytometry enhances prediction of immunotherapy response in head and neck cancer Open
View article: Genome-wide association study for lung cancer in 6531 African Americans reveals new susceptibility loci
Genome-wide association study for lung cancer in 6531 African Americans reveals new susceptibility loci Open
Despite lung cancer affecting all races and ethnicities, disparities are observed in incidence and mortality rates among different ethnic groups in the United States. Non-Hispanic African Americans had a high incidence rate of lung cancer …
View article: Genetic predisposition to altered blood cell homeostasis is associated with glioma risk and survival
Genetic predisposition to altered blood cell homeostasis is associated with glioma risk and survival Open
Glioma is a highly fatal and heterogeneous brain tumor with few known risk factors. Our study examines genetically predicted variability in blood cell indices in relation to glioma risk and survival in 3418 cases and 8156 controls. We find…
View article: Dissecting the biology of gliomagenesis: Evaluating the interaction between <i>IDH</i> tumor mutation and germline variants
Dissecting the biology of gliomagenesis: Evaluating the interaction between <i>IDH</i> tumor mutation and germline variants Open
Background The CCDC26 germline variant rs55705857 is causal for development of IDH mutant (IDHmut) adult glioma. However, ~60% of IDHmut patients do not carry the rs55705857 risk allele. We aimed to identify variants associated with develo…
View article: Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy
Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy Open
View article: Glioma immune microenvironment composition calculator (GIMiCC): a method of estimating the proportions of eighteen cell types from DNA methylation microarray data
Glioma immune microenvironment composition calculator (GIMiCC): a method of estimating the proportions of eighteen cell types from DNA methylation microarray data Open
A scalable platform for cell typing in the glioma microenvironment can improve tumor subtyping and immune landscape detection as successful immunotherapy strategies continue to be sought and evaluated. DNA methylation (DNAm) biomarkers for…
View article: Association of immunoglobulin E levels with glioma risk and survival
Association of immunoglobulin E levels with glioma risk and survival Open
Background Previous epidemiological studies have reported an association of serum immunoglobulin E (IgE) levels with reduced glioma risk, but the association between IgE and glioma prognosis has not been characterized. This study aimed to …
View article: Supplementary Table S3 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Table S3 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Table S3: Cox proportional hazards models of immune cell proportions and NMIBC patient outcomes (For Hannum Age Acceleration)
View article: Supplementary Figure S2 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Figure S2 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Figure S2: Blood immune cell profiles, age and age acceleration distribution of three groups assigned by partDSA algorithm in NMIBC patients
View article: Supplementary Figure S4 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Figure S4 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Figure S4: Blood immune cell profiles, age and age acceleration distribution of two clusters assigned by the SS-RPMM approach in NMIBC patients
View article: Supplementary Figure S3 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Figure S3 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Figure S3: Semi-Supervised Recursively Partitioned Mixture Model (SS-RPMM) for 10-year overall survival (OS) in NMIBC patients [For Hannum age acceleration]
View article: Supplementary Table S6 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Table S6 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Table S6: Characteristics of subjects of each group based on the grouping results from both partDSA and SS-RPMM in all NMIBC patients
View article: Supplementary Figure S4 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Figure S4 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Figure S4: Blood immune cell profiles, age and age acceleration distribution of two clusters assigned by the SS-RPMM approach in NMIBC patients
View article: Supplementary Table S1 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Table S1 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Table S1: Cox proportional hazards multivariable models for age acceleration of 601 NMIBC patients
View article: Supplementary Figure S1 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Figure S1 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Figure S1: The distribution of chronological age, methylation age, age acceleration, and each immune cell profile
View article: Supplementary Figure S1 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Figure S1 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Figure S1: The distribution of chronological age, methylation age, age acceleration, and each immune cell profile
View article: Supplementary Table S6 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Table S6 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Table S6: Characteristics of subjects of each group based on the grouping results from both partDSA and SS-RPMM in all NMIBC patients
View article: Supplementary Table S1 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Table S1 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Table S1: Cox proportional hazards multivariable models for age acceleration of 601 NMIBC patients
View article: Supplementary Table S5 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Table S5 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Table S5: The information of optimal CpGs selected by SS-RPMM using the model controlling for Pheno and Hannum age acceleration respectively
View article: Supplementary Table S3 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Table S3 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Table S3: Cox proportional hazards models of immune cell proportions and NMIBC patient outcomes (For Hannum Age Acceleration)
View article: Supplementary Table S4 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Table S4 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Table S4: Cox proportional hazards models of immune cell proportions and NMIBC patient outcomes (For Pheno Age Acceleration; NMIBC patients without BCG treatment; N = 512)
View article: Supplementary Figure S5 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Figure S5 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Figure S5: Kaplan-Meier analysis of 10-year overall survival based on the grouping results from both partDSA and SS-RPMM in all NMIBC patients [For Hannum age acceleration]
View article: Supplementary Figure S5 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Figure S5 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Figure S5: Kaplan-Meier analysis of 10-year overall survival based on the grouping results from both partDSA and SS-RPMM in all NMIBC patients [For Hannum age acceleration]
View article: Supplementary Table S4 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Table S4 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Table S4: Cox proportional hazards models of immune cell proportions and NMIBC patient outcomes (For Pheno Age Acceleration; NMIBC patients without BCG treatment; N = 512)
View article: Supplementary Table S2 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Table S2 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Table S2: Cox proportional hazards multivariable models for demographic and tumor characteristics of 601 NMIBC patients (For Hannum Age Acceleration)
View article: Supplementary Figure S2 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Figure S2 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Figure S2: Blood immune cell profiles, age and age acceleration distribution of three groups assigned by partDSA algorithm in NMIBC patients
View article: Supplementary Table S2 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Table S2 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Table S2: Cox proportional hazards multivariable models for demographic and tumor characteristics of 601 NMIBC patients (For Hannum Age Acceleration)
View article: Supplementary Table S5 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Table S5 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Table S5: The information of optimal CpGs selected by SS-RPMM using the model controlling for Pheno and Hannum age acceleration respectively
View article: Supplementary Figure S3 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Supplementary Figure S3 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Supplementary Figure S3: Semi-Supervised Recursively Partitioned Mixture Model (SS-RPMM) for 10-year overall survival (OS) in NMIBC patients [For Hannum age acceleration]
View article: Data from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Data from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes Open
Background: Immune profiles have been associated with bladder cancer outcomes and may have clinical applications for prognosis. However, associations of detailed immune cell subtypes with patient outcomes remain underexplored and may contr…